Abstract
An enzyme-linked immunosorbent assay (ELISA) for rabbit immunoglobulin (Ig) was developed in order to investigate serum levels achieved by therapeutic doses of rabbit antithymocyte globulin (ATG) and their relationship to in vitro serum lymphocytotoxic activity. Twenty renal allograft recipients treated for acute steroid resistant rejection with ATG were studied, where possible, before, during and following their treatment with ATG. During therapy, peak serum levels of rabbit Ig were in the range 20-101 micrograms/ml with one exception of 404 micrograms/ml. After treatment, levels gradually declined to zero within 12 weeks. All sera with lymphocytotoxic activity were absorbed with platelets and treated with dithiothreitol so that reactivity due to anti-HLA antibodies and autoantibodies produced by the patient could be differentiated from each other and from serum ATG. Nine patients had detectable serum ATG associated with in vitro lymphocytotoxic activity. In two cases the lymphocytotoxicity was attributed solely to ATG; two had only anti-HLA antibodies; in one patient the lymphocytotoxicity was due to a combination of ATG and anti-HLA antibodies; two had autoantibodies; and for two, cytotoxicity was initially due to ATG and subsequently to the development of autoantibodies. The serum levels of ATG achieved during treatment could thus be quantified, and the important distinction between anti-HLA antibodies, autoantibodies and ATG clearly made.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.